Liminatus Pharma (LIMN) Stock Price, News & Analysis

Company Overview

Liminatus Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases with significant unmet medical needs.

The company’s primary activities involve advancing pharmaceutical candidates through research and development, including preclinical and clinical testing. Publicly available information indicates that its work is centered on potential treatments in areas such as oncology and related therapeutic applications, rather than on marketed commercial products.

Liminatus Pharma is listed on the Nasdaq under the symbol LIMN. Detailed information about its specific product pipeline, geographic operations and leadership is limited in publicly available sources.

Key Stats

• Today's Range: $4.00 to $4.23
• 50-Day Range: $3.33 to $7.50
• 52-Week Range: $3.29 to $141.50
• Volume: 16,849 shs
• Average Volume: 31,408 shs
• Market Capitalization: $5.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Liminatus Pharma Stock Analysis - MarketRank™

Liminatus Pharma scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Liminatus Pharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Liminatus Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Liminatus Pharma is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liminatus Pharma is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.44% of the float of Liminatus Pharma has been sold short.

Short Interest Ratio / Days to Cover

Liminatus Pharma has a short interest ratio ("days to cover") of 2.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Liminatus Pharma has recently decreased by 38.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liminatus Pharma does not currently pay a dividend.

Dividend Growth

Liminatus Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Liminatus Pharma this week, compared to 1 article on an average week.

Search Interest

1 people have searched for LIMN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Liminatus Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.40% of the stock of Liminatus Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Liminatus Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LIMN
• Previous Symbol: NASDAQ:LIMN
• CIK: 1971387
• Web: liminatuspharma.com
• Phone: (213) 273-5453
• Fax: N/A
• Employees: 1
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($23.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -256.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.12
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($18.13) per share
• Price / Book: -0.23

Miscellaneous

• Outstanding Shares: 1,340,000
• Free Float: 1,082,000
• Market Cap: $5.60 million
• Optionable: N/A
• Beta: 5.30